Welcome Remarks and Introduction

CONFERENCE WELCOME: Thomas Thesing, Managing Partner, London Office and Head of London Corporate Group, Sidley (London)

A GLOBAL VIEW: Sharon Flanagan, Partner and Leader of Global Life Sciences Practice, Sidley (San Francisco)

UK LIFE SCIENCES INVESTMENT: Dr. Daniel Mahony, Chairman, The Bio Industry Association and UK Life Sciences Envoy

PHARMA AND BIOTECH: THE POWER OF COLLABORATION

INTRODUCED BY: Marie Manley, Partner and Leader of London Life Sciences Team, Sidley (London)

MODERATOR: Asher Rubin, Partner, Technology and Life Sciences Transactions, Sidley (Baltimore)

SPEAKERS:

Douglas Eby, Chief Executive Officer and Founder, Kyttaro 

Shaun Grady, Senior Vice President, Business Development Operations, AstraZeneca

Angus Grant, Executive Vice President, Business Development, Teva

Dr. Chris Sheldon, Senior Vice President, Head of Business Development, GSK 

PHARMA INVESTING: INDIVIDUAL STRATEGIES FOR SUCCESS - COMPANY BUILDING, IP-BACKED INVESTING, AND PATIENT CAPITAL

INTRODUCED BY: Josefine Sommer, Partner, Food, Drug and Medical Device, Sidley (Brussels)

MODERATOR: Annalisa Jenkins, BioPharma Thought Leader and Non-Executive Director, Genomics England

SPEAKERS:

Roel Bulthuis, Managing Partner, Syncona

Christopher LiPuma, Director, Fortress IP Fund

Stefan Linn, Managing Partner and CEO, L1 Health

Peter Thomas, Senior Principal, IQVIA 

FIRESIDE CHAT: A LIFE WELL-INVENTED

INTRODUCED BY: Michael Rosenblatt, MD, Senior Adviser, Flagship Pioneering, Bain Capital Life Sciences and Ascenta Capital

GUEST: Noubar Afeyan, Founder and CEO, Flagship Pioneering and Co-Founder and Chairman, Moderna 

MODERATOR: Robert Darwin, Partner, Private Equity and Life Sciences, Sidley (London) 

GETTING TO CLOSING: THE IMPACT OF ENERGISED FDI/ANTITRUST REGIMES ON HEALTHCARE DEAL CERTAINTY

INTRODUCED BY: Anne Robert, Partner, Antitrust/Competition, Sidley (Brussels) 

MODERATORS: 

Patrick Harrison, Partner, Antitrust/Competition, Sidley (London)

Sven De Knop, Partner, Global Arbitration, Trade and Advocacy, Sidley (Brussels)

SPEAKER:

Noel Watson-Doig, Senior Counsel, Business Development and Corporate, GSK

Private equity: STATE OF THE HEALTHCARE DEAL MARKET

INTRODUCED BY: Tony Drabble, Senior Principal, IQVIA 

MODERATOR: Chad D. Ehrenkranz, Partner, Healthcare, Sidley (New York)

SPEAKERS:

Luca Bonanomi, Managing Director, Private Equity Group, Blackstone 

Edward de Nor, Partner, GHO Capital Partners 

Kasper Gyldenvang, Vice President, Permira

Andre Valente, Partner, L.E.K. Consulting 

FOCUS ON WOMEN'S HEALTH: THE NEW DEAL FRONTIER

INTRODUCED BY: Eve-Anadel Coronado, General Counsel, Advanz Pharma

MODERATOR: Adriana Tibbitts, Partner, Technology and Life Sciences Transactions, Sidley (Baltimore)

SPEAKERS:

Nicole Hijnen, President of the Board, Freya Pharma Solutions

Daniel Karp, Chief Business Development Officer, Organon

Thomas Riisager, Chief Corporate Development Officer, Theramex

FUNDING AND STRATEGIC ALTERNATIVES FOR EMERGING LIFE SCIENCES COMPANIES - VENTURE CAPITAL, IPOs, PUBLIC MARKETS, AND BEYOND

INTRODUCED BY: Raymond Berglund,  Managing Director, Life Sciences and CFO Services, Alvarez & Marsal 

MODERATOR: Frank Rahmani, Partner, Sidley (Palo Alto)

SPEAKERS:

Michael Martin, Global Head, Takeda Ventures and Global Head, Center for External Innovation, Takeda Pharmaceuticals 

Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings

John Whittaker, Managing Director, Citi

CLOSING REMARKS

Robert Darwin, Partner, Private Equity and Life Sciences, Sidley (London)